



TIME (EDT) AGENDA: 18 th SEPTEMBER 2024			
08:15–09:00		Registration & breakfast Map Room Tea Lounge	
09:00–10:15 Session 1: Guastavino Room			
09:00–09:25		Welcome to the Biopharma Day 2024: Boston	
09:25–09:45		The potential of therapeutic mRNA — and how to measure it Andreas Czech BioNTech, Germany	
09:45–10:05		Challenges in designing, engineering, and testing humanized porcine donors for xenotransplantation Ranjith Anand eGenesis, USA	
10:15–10:55		10:15–11:20	R&D coffee break Map Room Tea Lounge & Product Display Area
		10:50–11:10	R&D product demo Product Display Area
10:55–12:20		11:20–12:45 Session 2: R&D McKim Room	
10:55–12:10		11:20–12:35	Use of nanopore sequencing in R&D
Use of nanopore sequencing in QC The art of GMP in the world of NGS: trials, tribulations, and a whole lot of acronyms — a success story Colette Côté PathoQuest, USA Using nanopore sequencing for mRNA vaccine quality control: a journey from R&D to GMP Helen Gunter The BASE Facility, The University of Queensland, Australia Adventitious agent screening by long-read NGS Serge Monpoeho Regeneron Pharmaceuticals, USA		Uncovering performance variability in cell lines for AAV vector production through integrated genomic and transcriptomic analysis Amit Mathur Sanofi, USA Nanopore sequencing at the intersection between the clinic and biotech Tasos Gogakos Arena BioWorks & Massachusetts General Hospital, USA NESSI-Seq: novel cfDNA methylation assays for biomarker discovery and precision medicine Chad Pollard Wasatch BioLabs, USA	
12:20–13:45		12:45–13:35	R&D lunch & networking McKim Atrium
12:20–13:35		12:45–13:25	Meet our service providers Map Room Tea Lounge
12:45–13:25		Meet our service providers McKim Atrium	
13:15–13:35		QC product demo Product Display Area	



13:45–14:45	Session 3: Biomanufacturing & QC Guastavino Room	13:35–14:45	Session 3: R&D McKim Room
13:45–14:35	Implementation of sequencing in a regulated environment David VanHoute Regeneron Pharmaceuticals, USA Sebastian B. Teitz veryTeitz Consulting, Germany Gaston Vondenhoff Lonza, The Netherlands	13:35–14:35	Use of nanopore sequencing in analytical development A sensitive sample preparation pipeline for adventitious virus detection using nanopore sequencing Charles A. Swofford MIT Center for Biomedical Innovation, USA Nanopore sequencing and functional screening of AAV genomes for optimal production and function Keith Connolly Modalis Therapeutics, USA Antibody discovery through post-vaccination single-cell transcriptomics and haplotype-resolved germline sequencing Scott Hickey Director, Commercial Applications, Oxford Nanopore Technologies
14:45–15:40	Coffee break Map Room Tea Lounge & Product Display Area		
15:10–15:30	QC & R&D product demo Product Display Area		
15:40–16:45	Session 4: Guastavino Room		
15:40–16:40	What is the future of nanopore sequencing in biopharma? Application of nanopore long-read sequencing to sterility testing for cell therapy products Stacy L. Springs MIT Center for Biomedical Innovation, USA Precision cell engineering enabled through nanopore sequencing Daniel K. Fabian Lonza, UK Microbial identification in biopharma Radhakrishna Tirumalai Merck & Co., USA Lakmal Jayasinghe Senior VP, R&D Biologics, Oxford Nanopore Technologies (panellist)		
16:40–16:45	Closing remarks		
16:45–18:00	Networking drinks		